Ken Griffin Dia Medica Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$2.8 - $4.49 $2,240 - $3,592	-800 Reduced 80.0%	200 $0
Q2 2024 Aug 14, 2024	SELL	$2.16 - $3.66 $864 - $1,464	-400 Reduced 28.57%	1,000 $2,000
Q4 2023 Feb 14, 2024	BUY	$2.05 - $2.99 $1,639 - $2,392	800 Added 133.33%	1,400 $3,000
Q3 2023 Nov 14, 2023	BUY	$2.56 - $4.4 $1,024 - $1,760	400 Added 200.0%	600 $1,000
Q2 2023 Aug 14, 2023	BUY	$1.53 - $4.4 $153 - $440	100 Added 100.0%	200 $0
Q4 2022 Feb 14, 2023	BUY	$1.13 - $1.62 $112 - $162	100 New	100 $0

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $118M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.